There are 3164 resources available
Invited Discussant 443O and 444O
Presenter: Monika Hegi
Session: Proffered paper session: CNS tumours
Resources:
Slides
Webcast
805MO - Real-world efficacy and safety of tisagenlecleucel (CTL019) for relapse or refractory follicular lymphoma patients included in the early access program through the French DESCAR-T registry
Presenter: Loic Ysebaert
Session: Mini oral session 1: Haematological malignancies
Resources:
Abstract
Slides
Webcast
Q&A
Session: Proffered paper session 1: GU tumours, non-prostate
Resources:
Webcast
Invited Discussant LBA83
Presenter: Fiona Blackhall
Session: Proffered Paper session: Non-metastatic NSCLC
Resources:
Slides
Webcast
Q&A
Session: Proffered paper session: CNS tumours
Resources:
Webcast
806MO - Phase Ib study of NT-I7 (efineptakin alfa), a long-acting IL-7, post-CD19-directed CAR T cell therapy in diffuse large B-cell lymphoma (DLBCL)
Presenter: Armin Ghobadi
Session: Mini oral session 1: Haematological malignancies
Resources:
Abstract
Slides
Webcast
Q&A
Session: Proffered Paper session: Non-metastatic NSCLC
Resources:
Webcast
807MO - High efficacy and safety of interleukin-6-knockdown CD19-targeted CAR-T cells in relapsed/refractory B-ALL patients
Presenter: Lei Yu
Session: Mini oral session 1: Haematological malignancies
Resources:
Abstract
Slides
Webcast
808MO - Value of early post-treatment FDG PET/CT in diffuse large B-cell lymphoma patients receiving chimeric antigen receptor T cell therapy
Presenter: Patrick Veit-haibach
Session: Mini oral session 1: Haematological malignancies
Resources:
Abstract
Webcast
Invited Discussant 805MO, 806MO, 807MO and 808MO
Presenter: Marco Ladetto
Session: Mini oral session 1: Haematological malignancies
Resources:
Webcast